| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PFKL |
| Uniprot No | P17858 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-780aa |
| 氨基酸序列 | AAVDLEKLR ASGAGKAIGV LTSGGDAQGM NAAVRAVTRM GIYVGAKVFL IYEGYEGLVE GGENIKQANW LSVSNIIQLG GTIIGSARCK AFTTREGRRA AAYNLVQHGI TNLCVIGGDG SLTGANIFRS EWGSLLEELV AEGKISETTA RTYSHLNIAG LVGSIDNDFC GTDMTIGTDS ALHRIMEVID AITTTAQSHQ RTFVLEVMGR HCGYLALVSA LASGADWLFI PEAPPEDGWE NFMCERLGET RSRGSRLNII IIAEGAIDRN GKPISSSYVK DLVVQRLGFD TRVTVLGHVQ RGGTPSAFDR ILSSKMGMEA VMALLEATPD TPACVVTLSG NQSVRLPLME CVQMTKEVQK AMDDKRFDEA TQLRGGSFEN NWNIYKLLAH QKPPKEKSNF SLAILNVGAP AAGMNAAVRS AVRTGISHGH TVYVVHDGFE GLAKGQVQEV GWHDVAGWLG RGGSMLGTKR TLPKGQLESI VENIRIYGIH ALLVVGGFEA YEGVLQLVEA RGRYEELCIV MCVIPATISN NVPGTDFSLG SDTAVNAAME SCDRIKQSAS GTKRRVFIVE TMGGYCGYLA TVTGIAVGAD AAYVFEDPFN IHDLKVNVEH MTEKMKTDIQ RGLVLRNEKC HDYYTTEFLY NLYSSEGKGV FDCRTNVLGH LQQGGAPTPF DRNYGTKLGV KAMLWLSEKL REVYRKGRVF ANAPDSACVI GLKKKAVAFS PVTELKKDTD FEHRMPREQW WLSLRLMLKM LAQYRISMAA YVSGELEHVT RRTLSMDKGF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PFKL(磷酸果糖激酶肝型)重组蛋白的3篇文献摘要示例(注：以下内容为模拟虚构，实际文献需通过学术数据库检索获取)：
---
1. **文献名称**：*Structural Insights into PFKL Regulation by Allosteric Modulators*
**作者**：Zhang Y. et al.
**摘要**：本研究通过重组表达人源PFKL蛋白，结合X射线晶体学揭示了其变构调控机制。发现ATP和果糖-2.6-二磷酸(F2.6-BP)通过结合特定结构域调节PFKL活性，为代谢疾病药物开发提供结构基础。
---
2. **文献名称**：*Recombinant PFKL Expression in E. coli: Optimization and Kinetic Analysis*
**作者**：Smith J.R. et al.
**摘要**：报道了在大肠杆菌中高效表达可溶性PFKL重组蛋白的方法，通过亲和层析纯化获得高纯度蛋白，并测定其酶动力学参数。结果显示重组PFKL的催化效率与天然酶高度一致。
---
3. **文献名称**：*PFKL-Dependent Glycolytic Flux Promotes Tumor Metastasis*
**作者**：Chen L. et al.
**摘要**：利用重组PFKL蛋白及基因编辑技术，证明PFKL通过增强糖酵解通量促进肿瘤细胞侵袭转移。体外实验显示，抑制PFKL活性可显著降低癌细胞能量代谢和迁移能力。
---
如需具体文献，建议通过PubMed或Web of Science检索关键词“PFKL recombinant protein”或“phosphofructokinase liver-type expression”获取最新研究。
**Background of PFKL Recombinant Protein**
Phosphofructokinase, liver type (PFKL), is a critical enzyme in glycolysis, catalyzing the irreversible conversion of fructose-6-phosphate to fructose-1.6-bisphosphate—a key regulatory step in glucose metabolism. As one of three tissue-specific isoforms (PFKM in muscle, PFKP in platelets, and PFKL in liver), PFKL plays a central role in hepatic glucose utilization and energy homeostasis. Dysregulation of PFKL is linked to metabolic disorders, including diabetes, cancer, and glycogen storage diseases, due to its impact on glycolytic flux and cellular ATP production.
Recombinant PFKL protein is engineered using molecular cloning techniques, typically expressed in *E. coli* or mammalian cell systems to ensure proper folding and enzymatic activity. This recombinant form retains the functional domains of native PFKL, including allosteric binding sites for regulators like ATP, AMP, and fructose-2.6-bisphosphate, which modulate its activity under varying metabolic conditions.
Researchers utilize recombinant PFKL to study glycolytic regulation, screen for metabolic disease therapeutics, and investigate mutations associated with Tarui disease (glycogenosis type VII). Its availability enables structural studies (e.g., X-ray crystallography) to elucidate mechanisms of enzyme activation/inhibition, aiding drug design. Additionally, recombinant PFKL serves as a tool in cancer research, where upregulated glycolysis (Warburg effect) is a hallmark, providing insights into targeting metabolic pathways for oncology treatments.
Overall, PFKL recombinant protein is a vital resource for advancing understanding of metabolic diseases and developing targeted interventions.
×
